An increasing number of ICIs, apart from anti-PD-1/PD-L1 and CTLA-4, such as anti-TIGIT and anti-LAG3, are under investigation and will soon gain approval for the treatment of unresectable HCC. Here, CTLA4 is linked to hepatocellular carcinoma.